Roche has agreed to buy U.S. cancer-therapy company Ignyta for $1.7 billion, the Swiss drugmaker’s latest move to shore up its oncology portfolio as its best-selling treatment faces generic competition.
from WSJ.com: US Business http://ift.tt/2C0Fn1O
via IFTTT
No comments:
Post a Comment